Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trial

At the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer.

In a head‑to‑head study against comparable agents from Amgen and Bristol Myers Squibb, the Roche drug reduced the risk of death by 44% in patients whose disease had progressed after prior therapy.

The trial focused on patients with KRAS G12C mutant tumors who had received earlier treatments, highlighting a potential survival advantage for this subgroup.

Roche’s results suggest its inhibitor may become a preferred option in this setting, though further regulatory review and broader clinical adoption will be needed.